

Please type a plus sign (+) in this box



PTOSB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Supplemental Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/650,025
	Filing Date	08/26/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Phyllis G. Spivack
	Attorney Docket Number	24852-501 CIP3

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue or Pub. Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
PS	A13	6,231,880	05/15/2001	Perrine	424	423	05/29/1998

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
PS	B10	WO	01/16106	Schering Aktiengesellschaft	03/08/2001		X

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
PS	C60	Adams and Elliott (2000). <i>Oncogene</i> 19: 6687-6692.
PS	C61	Bates et al. (1999). <i>Proc. American Society of Clinical Oncology</i> 18: 180a, Abstract No. 693
PS	C62	Foster et al. (1997). <i>Invest. New Drugs</i> 15: 187-194.
PS	C63	Gojo et al. (2002). <i>Blood</i> 100: Abstract No. 2198.
PS	C64	Gore and Carducci (2000). <i>Exp. Opin. Invest. Drugs</i> 9: 2923-2934.
PS	C65	Huang and Pardee (2000). <i>Molecular Medicine</i> 6: 849-866.
PS	C66	Johnstone, R. (2002). <i>Nature Reviews Drug Discovery</i> 1: 287-299.
PS	C67	Kelly et al. (2002). <i>Exp. Opin. Invest. Drugs</i> 11: 1695-1713.
PS	C68	Kelly et al. (2002). <i>Proc. American Society of Clinical Oncology</i> 21: 6b, Abstract No. 1831.
PS	C69	Kelly et al. (2001). <i>Proc. American Society of Clinical Oncology</i> 20: 87a, Abstract No. 344.
PS	C70	Kosugi et al. (2001). <i>Jpn. J. Cancer Res.</i> 92: 529-536.
PS	C71	Marshall et al. (2002). <i>J. Exp. Therapeutics and Oncology</i> 2: 325-332.
PS	C72	Piekarz et al. (2001). <i>Blood</i> 98: 2865-2868.
PS	C73	Prakash et al. (2001). <i>Invest. New Drugs</i> 19: 1-11.
PS	C74	Rha et al. (1993). <i>J. Korean Med. Sci.</i> 8:251-256.
PS	C75	Rifkind et al. (2002). 224 th ACS National Meeting, Boston, MA, Abstract No. 226.
PS	C76	Sandor et al. (2002). <i>Clinical Cancer Research</i> 8: 718-728.

Phyllis Spivack

6/29/05

BEST AVAILABLE COPY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
P3	C77	Secrist et al. (2003). <i>Curr. Opin. Invest. Drugs</i> 4:1422-1427.
P3	C78	Summerhayes, M. (2001). <i>J. Oncol. Pharm. Prac.</i> 7: 107-125.
PS	C79	Vigushin, D. (2002). <i>Current Opin. Invest. Drugs</i> 3: 1396-1402.
P3	C80	Warrell et al. (1998). <i>J. Natl. Cancer Institute</i> 90: 1621-1625.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. , filed , and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Phyllis Spivack	Date Considered	6/29/05
--------------------	-----------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY



Express Mail Label No.: EV 627295512 US
Date of Deposit: April 11, 2005

Page 1 of 1

Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/650,025
	Filing Date	08/26/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Phyllis G. Spivack
	Attorney Docket Number	24852-501 CIP3

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue or Pub. Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
PS	A13	2004/0002506	12/30/2004	Breslow et al.	514	310	04/01/2004
PS	A14	2004/0072735	04/15/2004	Richon et al.	514	9	03/04/2003
PS	A15	2004/0087631	05/06/2004	Bacopoulos et al.	514	352	08/26/2003
PS	A16	2004/0122101	06/24/2004	Miller et al.	514	575	06/19/2003
PS	A17	2004/0127522	07/01/2004	Chiao et al.	514	352	07/09/2003
PS	A18	2004/0132825	07/08/2004	Bacopoulos et al.	514	575	10/24/2003
PS	A19	2004/0266818	01/01/2004	Breslow et al.	514	263.4	10/25/2002

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. , filed , and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Phyllis Spivack	Date Considered	4/29/05
---------------------------	-----------------	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label No.: EV399525132US
Date of Deposit: March 14, 2005

1 of 1



Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/650,025
	Filing Date	08/26/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Spivack, P.
	Attorney Docket Number	24852-501 CIP3

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
PS	A10	6,451,334	09/17/02	Perrine	424	423	04/30/01
	A11	2003/0161830	08/28/03	Jackson et al.	duplicate		06/14/02
PS	A12	2004/0127523	07/01/04	Bacopoulos et al.	514	352	09/16/03

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C56	International Search Report for PCT/US03/06451, mailed October 27, 2003
	C57	International Preliminary Examination Report for PCT/US03/06451, mailed August 3, 2004
	C58	International Search Report for PCT/US04/27943, mailed March 7, 2005
PS	C59	Wu et al. (2001). "Negative Regulation of bcl-2 Expression by p53 in Hematopoietic Cells." <i>Oncogene</i> 20(2): 240-251, Abstract, Database CAPLUS on STN, Acc. No. DN134:293668.


*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Phyllis Spivack	Date Considered	6/29/05
--------------------	-----------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYC 316154v1

Date of Deposit: May 13, 2005



Please type a plus sign (+) in this box

+

PTO/SB (12-97)
OMB 0651-0031Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/650,025
	Filing Date	08/26/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Phyllis G. Spivack
	Attorney Docket Number	24852-501 CIP3

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue or Pub. Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
PS	A13	6,231,880	05/15/2001	Perrine	424	423	05/29/1998

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
PS	B10	WO	01/16106	Schering Aktiengesellschaft	03/08/2001		X

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
PS	C60	Adams and Elliott (2000). <i>Oncogene</i> 19: 6687-6692.
PS	C61	Bates et al. (1999). <i>Proc. American Society of Clinical Oncology</i> 18: 180a, Abstract No. 693
PS	C62	Foster et al. (1997). <i>Invest. New Drugs</i> 15: 187-194.
PS	C63	Gojo et al. (2002). <i>Blood</i> 100: Abstract No. 2198.
PS	C64	Gore and Carducci (2000). <i>Exp. Opin. Invest. Drugs</i> 9: 2923-2934.
PS	C65	Huang and Pardee (2000). <i>Molecular Medicine</i> 6: 849-866.
PS	C66	Johnstone, R. (2002). <i>Nature Reviews Drug Discovery</i> 1: 287-299.
PS	C67	Kelly et al. (2002). <i>Exp. Opin. Invest. Drugs</i> 11: 1695-1713.
PS	C68	Kelly et al. (2002). <i>Proc. American Society of Clinical Oncology</i> 21: 6b, Abstract No. 1831.
PS	C69	Kelly et al. (2001). <i>Proc. American Society of Clinical Oncology</i> 20: 87a, Abstract No. 344.
PS	C70	Kosugi et al. (2001). <i>Jpn. J. Cancer Res.</i> 92: 529-536.
PS	C71	Marshall et al. (2002). <i>J. Exp. Therapeutics and Oncology</i> 2: 325-332.
PS	C72	Piekarz et al. (2001). <i>Blood</i> 98: 2865-2868.
PS	C73	Prakash et al. (2001). <i>Invest. New Drugs</i> 19: 1-11.
PS	C74	Rha et al. (1993). <i>J. Korean Med. Sci.</i> 8:251-256.
PS	C75	Rifkind et al. (2002). 224 th ACS National Meeting, Boston, MA, Abstract No. 226.
PS	C76	Sandor et al. (2002). <i>Clinical Cancer Research</i> 8: 718-728.

Phyllis Spivack

6/29/05

BEST AVAILABLE COPY


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
P3	C77	Secrist et al. (2003). <i>Curr. Opin. Invest. Drugs</i> 4:1422-1427.
P3	C78	Summerhayes, M. (2001). <i>J. Oncol. Pharm. Prac.</i> 7: 107-125.
PS	C79	Vigushin, D. (2002). <i>Current Opin. Invest. Drugs</i> 3: 1396-1402.
P3	C80	Warrell et al. (1998). <i>J. Natl. Cancer Institute</i> 90: 1621-1625.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. , filed , and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Phyllis Spivack	Date Considered	6/29/05
--------------------	-----------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY



Express Mail Label No.: EV 627295512 US
Date of Deposit: April 11, 2005

Page 1 of 1

Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/650,025
	Filing Date	08/26/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Phyllis G. Spivack
	Attorney Docket Number	24852-501 CIP3

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue or Pub. Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
PS	A13	2004/0002506	12/30/2004	Breslow et al.	514	310	04/01/2004
PS	A14	2004/0072735	04/15/2004	Richon et al.	514	9	03/04/2003
PS	A15	2004/0087631	05/06/2004	Bacopoulos et al.	514	352	08/26/2003
PS	A16	2004/0122101	06/24/2004	Miller et al.	514	575	06/19/2003
PS	A17	2004/0127522	07/01/2004	Chiao et al.	514	352	07/09/2003
PS	A18	2004/0132825	07/08/2004	Bacopoulos et al.	514	575	10/24/2003
PS	A19	2004/0266818	01/01/2004	Breslow et al.	514	263.4	10/25/2002

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.


*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. , filed , and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Phyllis Spivack	Date Considered	4/29/05
---------------------------	-----------------	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label No.: EV399525132US
Date of Deposit: March 14, 2005

1 of 1



Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/650,025
	Filing Date	08/26/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Spivack, P.
	Attorney Docket Number	24852-501 CIP3

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
PS	A10	6,451,334	09/17/02	Perrine	424	423	04/30/01
	A11	2903/0161830	08/28/03	Jackson et al.	duplicate		06/14/02
PS	A12	2004/0127523	07/01/04	Bacopoulos et al.	514	352	09/16/03

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C56	International Search Report for PCT/US03/06451, mailed October 27, 2003
	C57	International Preliminary Examination Report for PCT/US03/06451, mailed August 3, 2004
	C58	International Search Report for PCT/US04/27943, mailed March 7, 2005
PS	C59	Wu et al. (2001). "Negative Regulation of bcl-2 Expression by p53 in Hematopoietic Cells." <i>Oncogene</i> 20(2): 240-251, Abstract, Database CAPLUS on STN, Acc. No. DN134:293668.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Phyllis Spivack	Date Considered	6/29/05
--------------------	-----------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYC 316154v1